戻る
化工社化工社 化学情報印刷レポート · 研究参考用
HRID 227686作成日:2026年10月24日

1-Fluoronaphthalene → N,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amine

https://huagongshe.com/ja/reaction/227686

反応式

関与物質

役割名称HCID仕込み量
反応物1-FluoronaphthaleneHCID 9450—
反応物DuloxetineHCID 60835—
反応物2,3:4,6-di-O-Isopropylidene-2-keto-L-gulonic acidHCID 65420—
反応物(S)-mandelic acidHCID 439616—
反応物3-(Dimethylamino)-1-(2-thienyl)-1-propanolHCID 11586409—
生成物N,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amineHCID 11573192—

反応手順

The preparation of the enantiomerically pure duloxetine intermediate (S)-AT-OL by its chiral resolution is exemplified in U.S. Pat. No. 5,362,886 (U.S. '886) and in WO 2004/031168, by the use of (S)-(+)-mandelic acid and (−)-2,3:4,6-Di-O-isopropylidene-2-keto-L-gulonic acid, respectively. The U.S. '886 patent describes the preparation of duloxetine by the chiral resolution of N,N-Dimethyl-3-(2-thienyl)-3-hydroxypropanamine (rac-AT-OL) with (S)-mandelic acid (Stage a), its reaction with fluoronaphtalene (Stage b) to give N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine (DNT), demethylation with phenyl chloroformate (Stage c), basic hydrolysis in the presence of (Stage d), and acidification (Stage e) in accordance with the following Scheme 1.

情報源と証拠

DOI10.6084/m9.figshare.5104873.v1
特許番号US07560573B2
出典データセットuspto-grants-2009_07
ORD IDord-b4e13c2f94f946e48272c9a7635dea3d
出典メモuspto-grants-2009_07